Based on improving new product visibility, benefits from...
Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.
Click Here or the flag on image above to change the background image